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Abstract 
Background: Pituitary adenylate cyclase-activating polypeptide (PACAP) plays several important roles in vasodila-
tion, neurotransmission, neuromodulation and neurotrophy, as well as activation of the trigeminovascular system. 
The aim of the present study was to explore the relationship between altered PACAP levels in peripheral blood and 
different types of headache.
Methods: The present study enrolled 101 outpatients with headache and 35 healthy control volunteers. Blood 
samples were collected from the cubital vein and peripheral blood mononuclear cells (PBMCs) were separated. Total 
mRNA in the PBMCs was extracted and the expression of PACAP mRNA was analyzed by quantitative-polymerase 
chain reaction (Q-PCR).
Results: There was a significant decrease in PACAP mRNA expression in the PBMCs of the migraine (M) group relative 
to the healthy control group. However, there were no significant differences in PACAP mRNA expression between 
the control group and tension-type headache (TTH), cluster headache (CH), or medication overuse headache (MOH) 
groups.
Conclusion: The PBMC levels of patients with migraine, but not other commonly seen headache types, exhibited a 
significant reduction in PACAP mRNA expression compared with healthy control subjects.
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Background
Headache can be classified as primary and secondary dis-
order. The latter was usually caused by another disease, 
trauma or any certain factors such as medication overuse, 
tumors or inflammation, while the primary headache was 
independent [1]. Approximately 90 % of all headaches are 
primary, and the most common subtypes are migraine 
(M), tension-type headache (TTH), and cluster headache 
(CH) [1–3]. The pathophysiology of headache includes 
traction to or irritation of the meninges and blood ves-
sels, because the brain itself is not sensitive to pain due 
to its lack of nociceptors [4]. These receptors, which are 
located at the extracranial arteries, middle meningeal 
artery, large veins, and cranial or spinal nerves, send pro-
jections up the length of the nerve fiber to nerve cells in 
the brain and signal that a part of the body hurts [5].
Pituitary adenylate cyclase-activating polypeptide 
(PACAP) is a member of the vasoactive intestinal pep-
tide (VIP)/secretin/glucagon peptide family, which is 
widely expressed in humans in the central nervous sys-
tem (CNS), endocrine glands, and peripheral organs [6]. 
Therefore, PACAP functions as a pleiotropic peptide that 
influences neurotransmission, neuromodulation, and 
neurotropic actions in the CNS, vessel dilation and regu-
latory mechanisms in the gastrointestinal, cardiovascular, 
reproductive, and respiratory systems, and anti-inflam-
matory activity in the immune system [7–9]. Moreo-
ver, recent studies have demonstrated an important role 
of PACAP in nociceptive processes [10–12], identified 
PACAP in the trigeminal system [12], and observed the 
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co-localization of nociceptors and PACAP [13, 14]. Addi-
tionally, Schytz et  al. [15] demonstrated that infusion 
of PACAP causes headache and vasodilatation in both 
healthy subjects and migraine patients. Taken together, 
these findings indicate that PACAP is involved in the 
pathogenesis of headache, but the exact roles it plays in 
different types of headache remain unclear.
Thus, the present study measured PACAP mRNA 
expression in peripheral blood mononuclear cells 
(PBMCs) of headache patients and healthy controls, and 
aimed to determine the relationships between altered 




The present study assessed 101 outpatients suffering from 
headache that visited the International Headache Center 
in the Department of Neurology at Chinese People’s Lib-
eration Army (PLA) General Hospital from April 2014 
to February 2015, and 32 healthy people were recruited 
as a control group. Patients were selected in accordance 
with the criteria of the International Classification of 
Headache Disorders, third edition, beta version (ICHD-3 
beta), and were categorized as follows: migraine (M, 
n =  43), tension-type headache (TTH, n =  23), cluster 
headache (CH, n  =  13), and medication overuse head-
ache (MOH, n = 22). The study groups were age-matched 
and the demographic and clinical characteristics of both 
patient and control populations were summarized in 
Table 1. A detailed questionnaire and examination were 
used to distinguish the type of headache in each patient, 
and any subjects (patients or controls) who displayed any 
other significant or serious disorders were excluded from 
the study. The study was approved by the Ethics Commit-
tee of the PLA General Hospital. All study participants 
signed an informed consent form, and all procedures 
were conducted in accordance with the Declaration of 
Helsinki.
Sample collection and preparation
There were no restrictions placed on the subjects regard-
ing food or drink intake. All study subjects provided 
blood samples (3 ml per subject). Each sample was drawn 
from the cubital vein, collected in an ice-cold glass tube 
containing the anticoagulant ethylenediaminetetraacetic 
acid (EDTA), and centrifuged within 1 h at 4000 rpm for 
5 min at 4 °C. After centrifugation, PBMCs in the cell pel-
lets were isolated using Ficoll-Paque PLUS (GE Health-
care; Piscataway, NJ, USA) and stored at −80 °C until the 
further use.
RNA extraction and reverse transcription
Using TRIpure LS reagent (Bioteke; Beijing, China), the 
total RNA was extracted according to the manufacturer’s 
protocol. Briefly, 1 ml of fresh blood was lysed with 3 ml 
TRIpure LS reagent. RNA was separated using chloro-
form, precipitated with isopropanol, and then washed 
with 70  % ethanol. Next, the RNA pellet was air-dried 
and dissolved in RNase-free water. To remove genomic 
DNA contamination, total RNA was incubated with 
RNase-free DNase, and then the purified RNA was quan-
tified with a spectrophotometer and stored at −80  °C. 
First-strand cDNA synthesis was performed for each 
RNA sample using the Sensiscript RT kit with random 
hexamers used to prime cDNA synthesis.
Table 1 The demographic characteristics comparisons between different types of headaches and healthy control group
Variable Healthy control M TTH CH MOH
Total 32 43 23 13 22
Male 14 (43.7 %) 15 (34.9 %) 7 (30.4 %) 11 (84.6 %) 3 (13.6 %)
Female 18 (56.3 %) 28 (65.1 %) 16 (69.6 %) 2 (15.4 %) 19 (86.4 %)
Age 35.46 ± 8.49 35.21 ± 10.44 45.17 ± 10.88 34.69 ± 10.12 46.18 ± 9.60
 <30 9 (28.1 %) 14 (32.6 %) 2 (8.7 %) 6 (46.2 %) 1 (4.5 %)
 30–40 15 (46.9 %) 12 (27.9 %) 6 (26.1 %) 4 (30.8 %) 5 (22.7 %)
 >40 8 (25 %) 17 (39.5 %) 15 (65.2 %) 3 (23.1 %) 16 (72.7 %)
Education
 Junior colleague or lower 12 (37.5 %) 26 (60.4 %) 17 (74.0 %) 9 (69.2 %) 17 (77.3 %)
 University or above 20 (62.5 %) 17 (39.6 %) 6 (26.0 %) 4 (30.8 %) 5 (22.7 %)
BMI
 Underweight (<18.5) 3 (9.4 %) 3 (7.0 %) 0 1 (7.7 %) 2 (9.1 %)
 Normal weight (18.5 to <23) 23 (71.9 %) 24 (55.8 %) 10 (43.5 %) 5 (38.5 %) 8 (36.4 %)
 Overweight (23 to <25) 4 (12.5 %) 6 (14.0 %) 5 (21.7 %) 2 (15.4 %) 6 (27.3 %)
 Obese (≥25) 2 (6.2 %) 10 (23.3 %) 8 (34.8 %) 5 (38.5 %) 6 (27.3 %)
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Quantitative‑polymerase chain reaction (Q‑PCR)
Primers were designed with Primer Premier 5.0 software 
and synthesized by the CapitalBio Corporation (Beijing, 
China) as follows: GAPDH: sense 5′-TGTTGCCATCA 
ATGACCCCTT-3′; anti-sense 5′-CTCCACGACGTACT 
CAGCG-3′;PACAP: sense 5′-TGTTCCCGTGGCTAGT 
TGC-3′; anti-sense 5′-ATCTGCTTCAGTTTAGTAA 
GGCTCT-3′.
The mRNA expression analyses of PACAP and phos-
phoglyceraldehyde dehydrogenase (GAPDH) were per-
formed by real-time PCR with SYBR Green Master Mix 
(Applied Biosystems; Foster City, USA). The thermocy-
cler conditions consisted of an initial holding at 50 °C for 
2 min and then at 95 °C for 10 min; this was followed by a 
two-step PCR program at 95 °C for 15 s and 60 °C for 60 s 
for 40 cycles. All data were collected and quantitatively 
analyzed on an ABI Prism 7500 Sequence Detection Sys-
tem (Applied Biosystems). The GAPDH gene served as 
an endogenous control to normalize for differences in the 
amount of total RNA in each sample. All quantities are 
expressed as the number of fold increase relative to that 
of GAPDH.
Statistical analysis
All data were processed using SPSS 19.0. Continuous 
variables are presented as the mean  ±  standard devia-
tion, and categorical variables as frequency counts and 
percentages. The normality of the data was tested with 
the Shapiro–Wilk test. Additionally, a correlation analy-
sis was performed using a Student’s unpaired t test and a 
single-factor analysis of variance (ANOVA) to determine 
whether any relationships existed between the patient 
characteristics and PACAP levels. Finally, the levels of 
PACAP were compared between the headache groups 
and healthy controls with a single-factor analysis of vari-
ance (ANOVA). A p value <0.05 was considered to indi-
cate statistical significance.
Results
The demographic characteristics comparisons 
between different types of headaches and healthy control 
group
Comparison of the demographic data among the differ-
ent headache groups and the control group is shown in 
Table  1. The ages of the 101 headache patients ranged 
from 14 to 69 years (M: 14–58 years, 35.21 ± 10.44 years; 
TTH: 24–69  years, 45.17  ±  10.88  years; CH: 
25–55  years, 34.69  ±  10.12  years; MOH: 23–63  years, 
46.18 ± 9.60 years), and the ages of the 32 control subjects 
ranged from 20 to 51 years (35.46 ± 8.49 years). Patients 
were also categorized into groups based on their body 
mass index (BMI; underweight, normal weight, over-
weight, and obese) and level of education (junior colleague 
or lower and university or above). A correlation analy-
sis revealed no significant correlation between PACAP 
mRNA levels and any patient characteristics, including 
age, gender, education, or BMI (p > 0.05) (Table 2).
The PACAP expression in the PBMCs of headache patients 
and the healthy controls
To determine the expression of PACAP mRNA in the 
PBMCs of headache patients, PBMCs were isolated and 
then evaluated using Q-PCR. To examine whether the 
level of PACAP mRNA expression in the PBMCs corre-
lated with headache, the data for M, TTH, CH and MOH 
groups were compared with the healthy control group 
respectively. Figure 1 shows that compared with control 
groups (n = 32; 0.6155 ± 0.1050), there was an obvious 
decrease in the level of PACAP expression in the PBMCs 
of the M group (n =  43; 0.3693 ±  0.0562; p =  0.0304). 
However, no significant difference was observed between 
the TTH, CH, MOH groups and control groups (p > 0.05) 
(Fig. 2), which suggested relative specificity for migraine.
The PACAP expression in the PBMCs of migraineurs
The results above suggested the PACAP expression in the 
PBMCs has correlation with migraine, but not with TTH, 
CH and MOH. Therefore, to investigate the relation-
ship between the PACAP expression and migraineurs’ 
characteristics, the migraine group was subdivided into 
male and female groups, interictal and attack groups, and 
with aura (MA) and without aura (MO) groups, but no 
significant differences in PACAP levels were observed 
(p  >  0.05) (Figs.  3, 4, 5). But Fig.  5 presents an uptrend 
of PACAP expression during migraine attack compared 
with interictal (0.3994 ± 0.3673 vs 0.2923 ± 0.3560).  
Table 2 PACAP mRNA levels and patient characteristics
n 2−△Ct (×10−3) p value
Gender >0.05
 Male 50 0.5333 ± 0.0829
 Female 83 0.4907 ± 0.0676
Age >0.05
 <30 32 0.4850 ± 0.0920 
 30–40 42 0.3954 ± 0.0601
 >40 59 0.6320 ± 0.0962
Education >0.05
 Junior colleague or lower 81 0.4558 ± 0.0528
 University or above 52 0.6146 ± 0.1042
BMI >0.05
 Underweight (<18.5) 9 0.4677 ± 0.2037
 Normal weight (18.5 to <23) 70 0.5166 ± 0.0675
 Overweight (23 to <25) 23 0.4123 ± 0.1104
 Obese (≥25) 31 0.4123 ± 0.1104
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Discussion
The present findings identified a relationship between 
the expression of PACAP mRNA in mononuclear cells 
derived from the peripheral blood of headache patients 
and different types of headache. A detailed analysis 
revealed that the PBMCs of migraineurs exhibited a sig-
nificantly lower level of PACAP mRNA expression than 
that of the control group, but there were no significant 
differences between the control group and TTH, CH, or 
MOH groups. Moreover, no significant correlation was 
observed between PACAP expression and age, gender, 
BMI, or the pain intensity and duration of headache in 
any headache group. These findings suggest that PACAP 
may be an effective marker for the identification of 
migraineurs and that the monitoring of these levels can 
inform a physician about the progression of migraine.
PACAP is a member of the VIP/secretin/glucagon 
peptide family encoded by the ADCYAP1 gene and is 
widely expressed in the CNS and peripheral tissues [16]. 
It has been reported that PACAP can induce neurogenic 
inflammation, neuronal activation and sensitization, and 
mast cell degranulation, which can all be involved in 
headache development [17]. Moreover, a previous study 
from our research group found that patients suffering 
from migraine exhibited lower plasma levels of PACAP 
compared to healthy control donors. Additionally, a 
negative correlation between interictal PACAP-38-LI 
and the duration of migraine was recently shown, but no 
relationships between plasma PACAP levels and gender, 
age, attack frequency, allodynia, or hormonal changes 
have been demonstrated [15]. Furthermore, although in 
the present study, no significant differences in PACAP 
Fig. 1 PACAP expression in migraine groups and controls. Com-
parison of −ΔCt of PACAP mRNA expression between migraine 
patients and the control groups showed that control group had 
higher −ΔCt than the patient group (controls: n = 35; mean −ΔCt: 
0.6155 ± 0.1050; migraineurs: n = 43; 0.3693 ± 0.0562; p = 0.0304)
Fig. 2 PACAP expression in CH, TTH, MOH groups and controls. Comparison of −ΔCt of PACAP mRNA expression between TTH, CH and MOH 
patients and the control groups showed no significant differences between the patient groups and controls.(controls: mean −ΔCt: 0.6155 ± 0.1050; 
TTH: 0.4683 ± 0.1448, p = 0.4035; CH: 0.4092 ± 0.1099, p = 0.2570; MOH: 0.5371 ± 0.1785, p = 0.8014)
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expression were found between the control group and 
TTH, CH, or MOH groups, the PACAP expression in 
migraineurs was significantly higher than that in the 
control group, which indicate that PACAP may act as a 
potential marker highly specific for migraine.
However, which types of cells that act as the major 
source of or cause the changes in PACAP levels in 
patients with migraine remain unclear. Migraine has 
been associated with disordered immune responses [18] 
and PACAP protein can be secreted by multiple types 
of cells, including neurons and immune cells [6]. Thus, 
the detection of PACAP expression in immune cells 
may explain the correlation between immune responses 
and migraine. Isolation of PBMCs in the present study 
revealed that migraineurs exhibited a lower level of 
PACAP mRNA than the healthy controls. This is in 
accordance with the results of a previous study from our 
research group which indicated that the level of PACAP 
mRNA in PBMCs reflects changes in plasma levels of 
PACAP [19]. However, in the present study, there was 
no relationship between the levels of PACAP mRNA in 
PBMCs and age, gender, BMI, or the pain intensity and 
duration of migraine. Further investigation is warranted 
to determine whether other peripheral tissue cells with 
similar patterns of PACAP expression can be described 
in the plasma and PBMCs.
The present study also assessed PACAP mRNA expres-
sion in the PBMCs of patients suffering from TTH, CH 
and MOH. In contrast to migraineurs, no significant dif-
ferences in PACAP mRNA expression were found com-
pared to the healthy control group, indicating that the 
PACAP mRNA level in PBMCs may be used as a marker 
for the differential diagnosis of migraine. To date, other 
than the calcitonin gene-related peptide (CGRP) [20], 
no markers has been identified,which could classify the 
headache into different subtypes.
In the present study, monitoring of PACAP mRNA 
expression in PBMCs during the progression of M 
revealed that PACAP levels were higher in the attack 
stage than the interictal stage. It was previously shown 
that migraineurs have elevated PACAP levels during 
the ictal period relative to the attack-free period [21]. 
Taken together, these findings suggest that PACAP may 
be involved in the development of migraine attacks and 
that the difference between these two stages may be 
due to different types of PACAP and various levels of 
protein and mRNA expression. Future studies should 
include a larger number of patients and perform detailed 
analyses investigating PACAP protein and mRNA levels 
simultaneously.
The findings of the present study indicate that PACAP 
mRNA levels in PBMCs may be used to conduct a differ-
ential diagnosis of migraine. Additionally, the changes in 
PACAP levels in PBMCs may represent a potential mech-
anism that links immune responses and the CNS.
Conclusion
The PBMC levels of patients with migraine, but not other 
commonly seen headache types, exhibited a signifi-
cant reduction in PACAP mRNA expression compared 
with healthy control subjects. The findings indicate that 
PACAP mRNA levels in PBMCs may be used to conduct 
Fig. 3 PACAP expression in female and male migraineurs. No sig-
nificant differences of PACAP expression in PBMCs of patients were 
observed between male and female migraineurs. (female: mean −
ΔCt 0.4003 ± 0.06623; male: 0.3114 ± 0.1052, p > 0.05)
Fig. 4 PACAP expression in migraine with (MA) and without aura 
(MO). No significant differences of PACAP expression in PBMCs of 
patients were observed between MA and MO groups. (MO: mean −
ΔCt 0.3843 ± 0.06496; MA: 0.3125 ± 0.1146, p > 0.05)
Fig. 5 PACAP expression in migraine attack and interictal groups. 
The results presents an uptrend of PACAP expression during 
migraine attack compared with interictal (attack groups: mean −ΔCt 
0.3994 ± 0.3673; interictal groups: 0.2923 ± 0.3560, p > 0.05)
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a differential diagnosis of migraine and the changes in 
PACAP levels in PBMCs may represent a potential mech-
anism that links immune responses and the CNS.
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